
Apalutamide Maintains Health-Related Quality of Life in TITAN Trial
Published: | Updated:
The addition of apalutamide to androgen deprivation treatment improved time to pain progression and other quality-of-life out­come measures in patients with metastatic castration-sensitive prostate cancer in the phase III TITAN trial.
